and can significantly reduce the burden of HPV-related genital warts and cancers among men, in addition to promoting herd immunity. Nevertheless, HPV4 coverage among boys remains low in most settings.
is safe and highly effective in preventing HPV infection and genital warts in men. Despite the potential for HPV4 vaccination to significantly reduce the burden of cancer among men, HPV vaccine ...
The quadrivalent HPV vaccine, developed by multinational pharmaceutical company Merck, was approved on Jan 8 for males on the Chinese mainland. The vaccine targets HPV types 6, 11, 16 and 18. The ...
It is the leading cause of cancer mortality in Kenya, with an estimated 3,200 deaths in 2020. It is also a significant global health concern, affecting millions of women worldwide.